Similarly, a prospective case-control study in CAD patients naïve to lipid-lowering therapy showed a significantly positive correlation between PCSK9 levels and the incidence and severity of CAD (11), and the effect of PCSK9 on CAD is primarily mediated by the increased atherogenic lipids and inflammatory markers. Here, PCSK9 is linked to coronary artery disorder.